Angel D. Pagan

Angel D. Pagan

Auto-generated profile, based on publicly available information

Angel D. Pagan

Laboratory of Inflammatory Skin Diseases, Department of Dermatology Icahn School of Medicine at Mount Sinai New York New York USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2023 in Allergy
Verified
Journal Article
Closed access
PFPaola Facheris
Paola Facheris
JRJoel M. Correa da Rosa
Joel M. Correa da Rosa
APAngel D. Pagan
Angel D. Pagan
MAMichael Angelov
Michael Angelov
EDEster Del Duca
Ester Del Duca
EGEmma Guttman‐Yassky
Emma Guttman‐Yassky

14 August 2023 in Allergy
Verified
Journal Article
Closed access
EDEster Del Duca
Ester Del Duca
HHHelen He
Helen He
YLYing Liu
Ying Liu
APAngel D. Pagan
Angel D. Pagan
EDEden David
Eden David
EGEmma Guttman‐Yassky
Emma Guttman‐Yassky

25 January 2023 in JID Innovations
Verified
Journal Article
Open access
CLCourtney Linkous
Courtney Linkous
APAngel D. Pagan
Angel D. Pagan
Chelsea ShopeChelsea Shope
Chelsea Shope
LALaura Andrews
Laura Andrews
ASAlan Snyder
Alan Snyder
MVManuel Valdebran
Manuel Valdebran
Laser speckle contrast imaging or laser speckle imaging (LSI) is a noninvasive imaging technology that can detect areas of dynamic perfusion or vascular flow. Thus, LSI has shown increasing diagnostic utility in various pathologies and has been employed for intraoperative, postoperative, and long-term monitoring in many medical specialties. Recently, LSI has gained traction in clinical dermatology because it can be effective in the assessment of pathologies that are associated with increased perfusion and hypervascularity compared with that of normal tissue. To date, LSI has been found to be highly accurate in monitoring skin graft reperfusion, determining the severity of burns, evaluating neurosurgical revascularization, assessing persistent perfusion in capillary malformations after laser therapy, and differentiating malignant and benign skin lesions. LSI affords the advantage of noninvasively assessing lesions before more invasive methods of diagnosis, such as tissue biopsy, while remaining inexpensive and exhibiting no adverse events to date. However, potential obstacles to its clinical use include tissue movement artifact, primarily qualitative data, and unclear impact on clinical practice given the lack of superiority data compared with the current standard-of-care diagnostic methods. In this review, we discuss the clinical applications of LSI in dermatology for use in the diagnosis and monitoring of vascular, neoplastic, and inflammatory skin conditions.

20 November 2023 in Allergy
Verified
Journal Article
Open access
RBRobert Bissonnette
Robert Bissonnette
JDJanet DuBois
Janet DuBois
PFPaola Facheris
Paola Facheris
EDEster Del Duca
Ester Del Duca
MKMadeline Kim
Madeline Kim
EGEmma Guttman‐Yassky
Emma Guttman‐Yassky
Background: RPT193 is an orally administered small molecule antagonist of the human C‐C motif chemokine receptor 4 (CCR4) that inhibits the migration and downstream activation of T‐helper Type 2 (Th2) cells. We investigated single‐ and multiple‐ascending doses of RPT193 in healthy subjects, and multiple doses of RPT193 in subjects with moderate‐to‐severe atopic dermatitis (AD).Methods: This was a first‐in‐human randomized, placebo‐controlled Phase 1a/1b monotherapy study (NCT04271514) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and CCR4 surface receptor occupancy in eligible healthy subjects and subjects with moderate‐to‐severe AD. Clinical efficacy and skin biomarker effects of RPT193 monotherapy were assessed as exploratory endpoints in AD subjects.Results: In healthy (n = 72) and AD subjects (n = 31), once‐daily RPT193 treatment was generally well tolerated, with no serious adverse events reported and all treatment‐emergent adverse events reported as mild/moderate. In AD subjects, numerically greater improvements in clinical efficacy endpoints were observed with RPT193 monotherapy versus placebo up to the end of the treatment period (Day 29), with statistically significant improvement, compared to Day 29 and placebo, observed 2 weeks after the end of treatment (Day 43) on several endpoints (p < .05). Moreover, significant changes in the transcriptional profile were seen in skin biopsies of RPT193‐treated versus placebo‐treated subjects at Day 29, which were also significantly correlated with improvements in clinical efficacy measures.Conclusions: To our knowledge, this is the first clinical study with an oral CCR4 antagonist that showed clinical improvement coupled with modulation of the cutaneous transcriptomic profile in an inflammatory skin disease.

6 October 2022 in Dermatological Reviews
Verified
Journal Article
Closed access
APAngel D. Pagan
Angel D. Pagan
KMKrystal Mitchell
Krystal Mitchell
JYJenna Yousif
Jenna Yousif
MHMichelle Henry
Michelle Henry

22 March 2023
Verified
Preprint
Open access
EDEster Del Duca
Ester Del Duca
HHHelen He
Helen He
YLYing Liu
Ying Liu
APAngel D. Pagan
Angel D. Pagan
EDEden David
Eden David
EGEmma Guttman-Yassky
Emma Guttman-Yassky